ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
value factor · long-only model fund

Foundry Healthcare Book-to-Market Value Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FBMHHYPOTHETICAL MODEL
Since ’99
+233%
Expense Ratio
0.45%
placeholder
Holdings
73
cap-weighted
Inception
Oct 2020
placeholder
Full Sharpe
0.32
Ann. Return (LS)
6.2%
Ann. Volatility
19.2%
Max Drawdown
-46.9%
Test Sharpe ’19–26
0.16
Test FF5 α (ann.)
8.6%
vs Fama-French 5
Test FF5 α t-stat
1.34
not significant
Monthly turnover
16%
of the long leg, per rebalance
Cumulative return (LS)
233%
over 329 months
This fund holds the long leg only
Long leg Sharpe
0.60
what this fund holds
Long leg ann. return
13.3%
buyable, long-only
Long-short Sharpe
0.32
requires shorting
Bottom bucket ann. return
7.1%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

329 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

73 of 73 · 100.0% of book
TickerCompanySectorMarket capWeight
1BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
15.83%
2OSCR
OSCAR HEALTH INCHealthcare$8.77B
12.06%
3BIO
BIO-RAD LABORATORIES INCHealthcare$8.15B
11.19%
4BEAM
BEAM THERAPEUTICS INCHealthcare$2.83B
3.89%
5AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
3.24%
6AGL
AGILON HEALTH INCHealthcare$2.17B
2.98%
7ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
2.71%
8HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
2.69%
9SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
2.50%
10MPLT
MAPLIGHT THERAPEUTICS INCHealthcare$1.72B
2.36%
11INVA
INNOVIVA INCHealthcare$1.60B
2.20%
12VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
2.19%
13INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
2.00%
14AKTS
AKTIS ONCOLOGY INCHealthcare$1.33B
1.83%
15XNCR
XENCOR INCHealthcare$1.30B
1.78%
16AZTA
AZENTA INCHealthcare$1.21B
1.67%
17NUTX
NUTEX HEALTH INCHealthcare$1.12B
1.54%
18BIOA
BIOAGE LABS INCHealthcare$1.01B
1.39%
19JANX
JANUX THERAPEUTICS INCHealthcare$992M
1.36%
20LBRX
LB PHARMACEUTICALS INCHealthcare$901M
1.24%
21SLDB
SOLID BIOSCIENCES INCHealthcare$859M
1.18%
22AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
1.13%
23BBNX
BETA BIONICS INCHealthcare$771M
1.06%
24RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
1.03%
25CSTL
CASTLE BIOSCIENCES INCHealthcare$733M
1.01%
26BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS INCHealthcare$686M
0.94%
27NGNE
NEUROGENE INCHealthcare$590M
0.81%
28FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.79%
29FLGT
FULGENT GENETICS INCHealthcare$573M
0.79%
30CTNM
CONTINEUM THERAPEUTICS INCHealthcare$532M
0.73%
31EIKN
EIKON THERAPEUTICS INCHealthcare$529M
0.73%
32ARVN
ARVINAS INCHealthcare$517M
0.71%
33DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.71%
34SGMT
SAGIMET BIOSCIENCES INCHealthcare$479M
0.66%
35PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.62%
36VREX
VAREX IMAGING CORPHealthcare$444M
0.61%
37BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.60%
38CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.59%
39ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.55%
40UPB
UPSTREAM BIO INCHealthcare$382M
0.52%
41ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.50%
42LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.43%
43TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.37%
44QTTB
Q32 BIO INCHealthcare$255M
0.35%
45ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.33%
46RXST
RXSIGHT INCHealthcare$230M
0.32%
47UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.31%
48KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.29%
49RNA
ATRIUM THERAPEUTICS INCHealthcare$208M
0.29%
50IMUX
IMMUNIC INCHealthcare$207M
0.28%
51DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.28%
52ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.28%
53AMWL
AMERICAN WELL CORPHealthcare$199M
0.27%
54TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.27%
55ACOG
ALPHA COGNITION INCHealthcare$185M
0.25%
56INGN
INOGEN INCHealthcare$178M
0.24%
57KRRO
KORRO BIO INCHealthcare$177M
0.24%
58ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.24%
59CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.23%
60LENZ
LENZ THERAPEUTICS INCHealthcare$162M
0.22%
61PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.19%
62VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.18%
63AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.18%
64CUE
CUE BIOPHARMA INCHealthcare$126M
0.17%
65ICCC
IMMUCELL CORPHealthcare$101M
0.14%
66RLYB
RALLYBIO CORPHealthcare$87M
0.12%
67FRMM
FORUM MARKETS INCHealthcare$83M
0.11%
68ACET
ADICET BIO INCHealthcare$76M
0.10%
69AGPU
AXE COMPUTE INCHealthcare$72M
0.10%
70LONA
LEONABIO INCHealthcare$68M
0.09%
71IMA
IMAGENEBIO INCHealthcare$61M
0.08%
72XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.07%
73TIL
INSTIL BIO INCHealthcare$50M
0.07%

Full long-leg book as of July 2026 · cap-weighted · total market cap $72.77B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

73 classified
Value
Blend
Growth
Large
Mid
Small
12%1
27%2
·
36%16
·
·
24%53
<1%1
·

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 57% toward Large, 14% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt57% → Large
SmallLarge
Value ↔ growth tilt14% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1999July 2026; the right-hand end is the same value as the box’s dot. 73 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    75.9%
    Margin
    0.9%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    7.1 days
    Margin
    -0.1 days
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 73 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.6 (95% CI 1.0-1.9)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
15.4%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 329 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.60x
within
parametric
1.41x
within
cornish fisher
1.28x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1980
Entirely since publication
All 329 months of our record post-date the 1980 paper.
Sharpe 0.326.2% p.a.March 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
65%
17 of 26 3-year windows made money
Worst window
-0.79
Sharpe, March 2007 – February 2010
March 1999July 2026
Median Sharpe
0.26
Dispersion
0.60
Best window
1.44

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since March 1999
Trailing
PeriodLong legLong-short
1 yearcum.81.5%27.8%
3 yearsp.a.21.5%6.1%
5 yearsp.a.4.1%2.2%
10 yearsp.a.8.1%0.6%
Since inceptionp.a.11.4%4.5%
Calendar years
YearLong legLong-short
20267 mo24.7%14.9%
202541.2%9.6%
20247.1%3.5%
2023-14.0%-16.2%
2022-19.3%2.1%
2021-11.2%-16.5%
202038.2%10.3%
201922.6%7.3%
2018-7.4%-16.6%
201717.7%1.2%
2016-3.5%8.5%
20156.2%-0.1%
201429.6%2.3%
201344.0%-3.5%
201215.5%-4.7%
201119.8%12.3%
201026.0%15.8%
200910.2%-4.6%
2008-35.3%-16.8%
2007-3.3%-8.6%
200617.1%15.0%
200513.0%5.7%
200423.0%24.3%
200357.9%35.5%
2002-16.3%8.5%
200124.7%41.6%
200061.0%26.2%
199910 mo-9.5%-6.4%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FBMH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-10-09 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$72.77B

Methodology

The Foundry Healthcare Book-to-Market Value Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Book-to-Market Value signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.